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The GM1 ganglioside is a mono-sialylated glycosphingolipid present in the outer layer of 
the cell plasma membrane and abundant in neurons. Numerous in vitro and in vivo studies 
highlight the role of GM1 not only as a structural component but also as a functional 
regulator. Indeed, GM1 enrichment in membrane microdomains promotes neuronal 
differentiation and protection, and the GM1 content is essential for neuronal survival and 
maintenance. 
Despite many lines of evidence on the GM1-mediated neuronotrophic effects, our 
knowledge on the underlying mechanism of action is scant. Recently, the oligosaccharide 
chain of GM1 (oligoGM1) has been identified as responsible for the neuritogenic properties 
of the GM1 ganglioside in neuroblastoma cells. The oligoGM1-mediated effects depend on 
its binding to the NGF specific receptor TrkA, thus resulting in the TrkA-MAPK pathway 
activation. 
In this context, my PhD work aimed to confirm the role of the oligoGM1, as the bioactive 
portion of the entire GM1 ganglioside, capable of enhancing the differentiation and 
maturation processes of mouse cerebellar granule neurons.  
First, we performed time course morphological analyses on mouse primary neurons plated 
in the presence or absence of exogenously administered gangliosides GM1 or GD1a (direct 
GM1 catabolic precursor). We found that both gangliosides increased neuron clustering and 
arborization, however only oligoGM1 and not oligoGD1a induced the same effects in 
prompting neuron migration. This result suggests the importance of the specific GM1 
saccharide structure in mediating neuronotrophic effects. Then we characterized 
biochemically the oligoGM1-mediated effect in mouse primary neurons, and we observed a 
higher phosphorylation rate of FAK and Src proteins which are the intracellular key 
regulators of neuronal motility. Moreover, in the presence of oligoGM1 cerebellar granule 
neurons showed increased level of specific neuronal markers (e.g., β3-Tubulin, Tau, 
Neuroglycan C, Synapsin), suggesting an advanced stage of maturation compared to 
controls. In addition, we found that the oligoGM1 accelerates the expression of the typical 
ganglioside pattern of mature neurons which is characterized by high levels of complex 
gangliosides (i.e., GM1, GD1a, GD1b, and GT1b) and low level of the simplest one, the 
GM3 ganglioside. 
To study the mechanism of action of the oligoGM1, we used its tritium labeled derivative 
and we found that the oligoGM1 interacts with the cell surface without entering the cells. 
This finding suggests the presence of a biological target at the neuronal plasma membrane. 
 Abstract  
3 
 
Interestingly, we observed the TrkA-MAP kinase pathway activation as an early event 
underlying oligoGM1 effects in neurons. 
Our data reveal that the effects of GM1 ganglioside on neuronal differentiation and 
maturation are mediated by its oligosaccharide portion. Indeed, oligoGM1 interacts with the 
cell surface, thus triggering the activation of intracellular biochemical pathways that are 
responsible for neuronal migration, dendrites emission and axon growth.  
Overall, our results point out the importance of oligoGM1 as a new promising neurotrophic 
player. 
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Abbreviations: 
BSA: bovine serum albumine 
CGN: cerebellar granule neurons 
CMP: cytidine-5′-monophosphate 
CNS: central nervous system 
Ctx-B: B subunit of cholera toxin 
ERK1/2: extracellular signal-regulated 
protein kinases 1 and 2 
FAK: focal adhesion kinase 
FBS: fetal bovine serum 
GDNF glial-derived growth factor 
Hp-TLC: high performance thin layer 
chromatography 
HRP: horse raddish peroxidase 
MAPK: mitogen activated protein kinase 
NCX: Na/Ca exchanger  
NGF: nerve growth factor 
OligoGD1a: GD1a-oligosaccharide 
OligoGM1: GM1-oligosaccharide 
PBS: phosphate saline buffer 
PD: Parkinson’s Disease 
PNS: peripheric nervous system 
PVDF: polyvinylidene difluoride 
SDS-PAGE: sodium-dodecyl-sulphate-
polyacrylamide gel electrophoresis 
Trk: tropomyosin receptor kinase 
TRPC5: Transient receptor potential 
channel 5  
UDP: uridine diphosphate
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1. GM1 structure, nomenclature and structural properties 
GM1 belongs to the family of glycosphingolipids containing at least one sialic acid residue 
(neuronaminic acid, Neu), i.e. gangliosides. In particular, GM1 contains a single residue of 
sialic acid and belongs to the ganglio- tetrahexosyl series, with formula β-Gal-(1-3)-β-
GalNAc-(1-4)-[α-Neu5Ac-(2-3)-]-β-Gal-(1-4)-Glc-(1-1)-Ceramide, represented in Figure 
I1 (panel A). 
 
Figure I1. Schematic representation of gangliosides. A: GM1 ganglioside consists of neutral core 
structure Galβ3-GalNAcβ4-Galβ4 -Glcβ1-Cer and one N-acetylneuraminic acid attached to the inner 
galactose. B: Schematic representation of major gangliosides in vertebrate brain: GM1, GD1a, GD1b 
and GT1b. Blu circle = Glucose. Yellow circle = Galactose. Yellow square = GalNAc. Purple 
rhombus = Neu5Ac. 
 
Several Neu structures have been discovered and in humans the most common is 5-N-acetyl 
derivative (Neu5Ac or NANA) (Schauer et al. 1982). 
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The specific names for the gangliosides provide information about their structure, according 
to International Union of Pure and Applied Chemistry (IUPAC)- International Union of 
Biochemistry (IUB) nomenclature (Chester 1998). The capital letter G refers to ganglioside, 
and the subscript M indicates that the molecule contains one unit of sialic acid. The 
numbered subscript refers to the carbohydrate sequence that is attached to the ceramide. In 
particular, 1 stands for Gg4 neutral series, i.e.  β-Gal-(1-3)-β-GalNAc-(1-4)-β-Gal-(1-4)-Glc 
oligosaccharide structure (Aureli et al. 2016). 
Like all sphingolipids, the hydrophobic portion of GM1 is represented by the ceramide. 
There are different types of ceramides in nature and generally consist of a basic long 
hydrophobic chain base, which is called sphingosine (Sph) attached to a fatty acid by amidic 
bond. Within the brain, sphingosine may have 18 or 20 carbon atoms (C18-C20) at different 
ratios in nervous system (Karlsson 1970) with C20-Sph barely detectable in the fetus but 
becoming the most represented sphingosine in adult human brain (Sonnino and Chigorno, 
2000). Regarding the fatty acid of ceramide, stearic acid accounts for 90% of that present in 
the nervous system. 
In biological environments, GM1 has a net negative charge due to the presence of sialic acid. 
The presence of the pentasaccharidic portion confers generally a high degree of 
hydrophilicity, both for sialic acid and for the intrinsic hydrophilicity of sugars. The 
combination of the hydrophobic lipid portion and the hydrophilic oligosaccharide portion 
gives the GM1 molecule an amphiphilic character that characterizes its chemical-physical 
behaviors but also the biological ones. 
In aqueous solution, GM1 is soluble and tends to form ellipsoidal micellar aggregates due to 
the hydrophobic effect (Cantù et al. 1986). GM1 micelles form at very low concentration. 
In fact, the minimum micellar concentration of GM1 is 10-8-10-9 M to indicate that regardless 
of its concentration, in aqueous solution, the concentration of GM1 monomers cannot exceed 
that of minimum micellar concentration (Sonnino et al. 1994; Corti et al. 1980; Ulrich-Bott 
and Wiegandt 1984).  
Aggregative properties are of significant relevance when gangliosides are exogenously 
administered to cells. In fact, only the monomeric GM1 becomes part of the plasma 
membrane of the cells, while the micelles interact with the plasma membrane and are 
internalized by endocytosis, to be then metabolized in the endo-lysosomal system (Valsecchi 
et al. 1992; Saqr et al. 1993). 
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GM1, like all gangliosides, is stably inserted into the outer layer of the plasma membrane 
with the portion of the ceramide inserted into the lipid bilayer which interacts via 
hydrophobic interactions with the surrounding lipids. The oligosaccharide is exposed in the 
extracellular aqueous environment and its conformation has been studied in detail by means 
of nuclear magnetic resonance (NMR) experiments and molecular modeling (Acquotti et al. 
1990; Brocca et al. 1998; 2000; Fantini and Yahi 2015). The bonds between the Gal-GalNAc 
and Gal-Glc disaccharides are more dynamic with 2 possible conformations, while the 
internal trisaccharide GalNAc-(NeuAc)-Gal is considered as a rigid block with one possible 
conformation. The link between Glc and ceramide suggests that the entire oligosaccharide 
head of GM1 is placed perpendicular to the plasma membrane (Acquotti et al. 1990; Brocca 
et al. 2000). 
The GM1 monomers are then distributed in membrane as a group of conformers giving high 
dynamism to the structure. In this way the monomers can interact, through the lipid 
component and the oligosaccharide component, both with the membrane proteins and with 
each other, segregating and clustering in the membrane (Brocca et al. 1998; Mauri et al. 
2012). 
To note, crystallographic studies have been useful to visualize three-dimensional structures 
of the GM1 pentasaccharide recognized by cholera toxin, AB5 toxin, and polyoma virus 
(Holmgren et al. 1975; Neu et al. 2008; Nagatsuka et al. 2013) In these structures, the outer 
branch of the carbohydrate chain is involved in the interactions with these hazardous binders. 
The pentasaccharide conformations differ among these complexes and are deviated from the 
NMR structures, suggesting that GM1 glycan undergoes conformational alteration upon 
binding to proteins in a ligand-dependent manner (Yagi-Utsumi and Kato 2015). 
2. GM1 metabolism and topology 
Gangliosides and therefore GM1 are particularly enriched in the nervous system cells. They 
abound especially in the membranes of neurons but have also been identified in glial cells 
and GM1 has also been found in astrocytes, oligodendrocytes and microglia. 
De novo biosynthesis of GM1, as for all gangliosides, occurs inside the cells, at the level of 
Golgi compartment, the intracellular organelle most enriched in glycosphingolipids. In the 
Golgi the assembly of the oligosaccharide head occurs by the sequential adding of the 
individual activated saccharide units by the action of glycolipid glycosyltransferases, a 
pathway primarily identified by Roseman in 1970 (Roseman et al. 1970).  
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As shown in Figure I2, complex gangliosides are stepwise synthesized from simpler ones. 
The first ganglioside, GM3, is produced from lactosylceramide by cytidine-5′-
monophosphate (CMP)-sialic acid:LacCer α2-3 sialyltransferase (ST-I), which adds an α2, 
3-linked sialic acid to lactosylceramide. Further addition of sialic acids by CMP-sialic 
acid:GM3 α2-8 sialyltransferase (ST-II) and CMP-sialic acid:GD3 α2-8 sialyltransferase 
generates GD3 and GT3, respectively. These simple gangliosides constitute the complex 
gangliosides belonging to the a-, b-, and c-series, respectively. Elaboration of the ganglioside 
structures is achieved by other specific glycosyltransferases, such as UDP-
GalNAc:LacCer/GM3/GD3/GT3 β1-4 N-acetylgalactosaminyltransferase (GalNAcT), 
UDP-Gal:GA2/GM2/GD2/GT2 β1-3 galactosyltransferase, CMP-sialic 
acid:GA1/GM1/GD1b/GT1c α2-3 sialyltransferase, and CMP-sialic 
acid:GM1b/GD1a/GT1b/GD3 α2-8 sialyltransferase (Svennerholm et al. 1994; Yu et al. 
2004; 2008). 
 
 
Figure I2: Structure and metabolic pathways of gangliosides. β-gal, lysosomal acid β-
galactosidase; Cer, ceramide; GALC, galactosylceramidase; GalNAc-T, N-
acetylgalactosaminyltransferase I (GA2/GM2/GD2/GT2-synthase); GalT-I, galactosyltransferase I 
(lactosylceramidesynthase); GalT-II, galactosyltransferase II (GA1/GM1/GD1b/GT1c-synthase); 
GalT-III, galactosyltransferase III (galactosylceramidesynthase); GLCC, glucosylceramidase; GlcT 
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glucosyltransferase (glucosylceramide synthase); GM2A, GM2 activator protein; HEX, b-N-
acetylhexosaminidase; SA, sialic acid; SAP, saposin; ST-I, sialyltransferase I (GM3-synthase); ST-
II, sialyltransferase II (GD3-synthase); ST-III, sialyltransferase III (GT3-synthase); ST-IV; 
sialyltransferase IV (GM1b/GD1a/GT1b/GQ1c-synthase); ST-V, sialyltransferase V 
(GD1c/GT1a/GQ1b/GP1c-synthase); ST-VII, sialyltransferase VII (GD1a/GT1aa/GQ1ba/GP1ca-
synthase). In this Figure, the nomenclature of gangliosides is based on that of Svennerholm 
(Svennerholm 1963). 
 
During the normal turnover of plasma membranes, GM1 is degraded at the level of the endo-
lysosomal compartment, more precisely within the intralysosomal vesicles as revealed by 
immunoelectron microscopy studies (Fürst et al. 1992; Möbius et al. 1999). As for the 
synthetic pathway, the degradation process occurs in a stepwise manner, mainly by water-
soluble but often protein and membrane associated hydrolases with the help of lipid binding 
proteins, SAP (Kolter et al. 2005).  
In this way a first action of the β-galactosidase on GM1 forms the GM2 which becomes 
substrate of the β-hexosaminidase to give GM3. The action of lysosomal sialidases, mainly 
Neu1 and Neu4, generates lactosylceramide, which after hydrolysis by galactosidase and 
glucosylcerebrosidase leads to the formation of ceramide which can be further degraded or 
recycled.  
It is important to note that the genetic alteration of one of the enzymes involved in the 
metabolism of GM1 and other glicosphingolipids is associated with several cellular 
functional anomalies leading to severe pathological conditions (Breiden and Sandhoff 2018).  
Studies with genetically modified mice by disruption of ganglioside synthetic enzymes 
allowed to investigate the role of each molecular specie (Sheikh et al. 1999; Proia 2003; 
Furukawa et al. 2004). These include the much-studied β4galnT1-/-  and β4galnT+/-  mice 
null or heterozygous for GM2/GD2 synthase, which have provided key clues on the 
functions of gangliosides and especially GM1 (Furukawa et al. 2002, 2004; Schengrund 
2015). 
On the other hand, the alteration of the enzymes involved in the catabolism of gangliosides 
are associated with pathological syndromes belonging to gangliosidosis family (Sandhoff 
2013). 
 
GM1 is mainly represented on the neuronal plasma membrane (Tettamanti et al. 1973), 
where initially, thanks to studies using ligands such as B subunit of Cholera toxin and anti-
GM1 antibodies with high-affinity for GM1, an enrichment of GM1 was observed 
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exclusively at presynaptic and postsynaptic membranes of nerve endings (Hansson et al. 
1977; Ledeen et al. 1978). Subsequent studies have revealed the presence of GM1 and other 
gangliosides over large portions of the neuron comprising the axolemma and the soma, 
although their concentration was found to be lower in perikaryon and higher in synaptic 
terminals (Devries et al. 1980). This non-homogeneous distribution of gangliosides is due 
to the rapid vesicular axonal transport to nerve endings (Forman et al. 1972) and, in parallel, 
to retrograde transport from terminations to the neuronal soma, to be re-used or 
metabolically processed (Aquino et al. 1987). 
 
In the plasma membrane, GM1 is distributed and segregated in lipid microdomains which 
are called lipid rafts. From an operational point of view, they are known as detergent resistant 
membrane that are isolated as low-density fractions by density gradient ultracentrifugation. 
These microdomains are enriched in gangliosides, sphingomyelin, cholesterol, 
phosphatidylinositol but are also populated by lipid-binding proteins (Simons and Sampaio, 
2011). Although they are considered lipid raft markers, actually gangliosides represented 
only 6- 7% of the lipids present in microdomains of primary neurons, with more than 50% 
consisting of glycerophospholipids (Sonnino et al. 2007). Furthermore, GM1 is also the less 
abundant with GD1a, GD1b and GT1b representing the majority of gangliosides in mature 
neurons (structures in Figure I1, panel B). However, GD1a is considered as a reserve pool 
of GM1 which is easily converted into GM1 by membrane endogenous sialidase Neu3 
(Sonnino et al. 2011; Miyagi et al. 2012).  
In fact, another important site of gangliosides metabolism in addition to the endo-lysosomal 
system is represented by the plasma membrane, which hosts glycohydrolases and sialidases 
for the local surface and fine remodeling of the glycolipid composition (Aureli et al. 2014). 
Membrane microdomains represent important cellular signaling platforms through which 
cells receive signals from outside and initiate reactions that involve cellular responses and 
changes. Despite their paucity, gangliosides are recognized as fundamental elements with an 
active role not only for the formation, stabilization and dynamics of microdomains (Sonnino 
et al. 2007; Ohmi et al. 2012), but also because they represent primary players in initiating 
and regulating the signaling pathways. This is particularly true for GM1, whose levels are 
finely regulated during the processes of differentiation and neuronal survival (addressed in 
the section: Functional role of GM1 in the Nervous System). 
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In addition to the plasma membrane, small amounts of gangliosides have also been found in 
the membrane of the mitochondria, nucleus and in the endoplasmic reticulum, but little is 
known about their origin and metabolism in these organelles (Breiden and Sandhoff 2018). 
GM1 and GD1a were found in the nuclear envelope along with Neu3 sialidase (Ledeen et 
al. 2011). Here the GM1 plays an important role in regulating the activity of the Na/Ca 
exchanger (NCX) and thus contributing to the modulation of nuclear calcium levels (Xie et 
al. 2002). 
3. Functional role of GM1 in the Nervous System 
The central and peripheral nervous tissues are the sites most abundant in gangliosides 
(Ledeen and Wu 2018). In the brain, gangliosides concentrate in the gray substance with 
respect to white matter, indicating that neurons are the main site of gangliosides 
(Svennerholm et al. 1994). As mentioned above, gangliosides are involved in a wide range 
of biological processes in addition to their role as simple structural membrane components. 
The content and composition of gangliosides change significantly during differentiation, 
aging and neuronal damage (Ngamukote et al. 2007; Yu et al. 2009). Among all the 
gangliosides, GM1 is surely the most studied for its neurotrophic and neurorestorative 
properties (Aurelie et al. 2016; Ledeen and Wu 2015). Its functions have been discovered 
through in vivo studies, with the use of genetically modified animal models with alterations 
in the biosynthetic pathways of gangliosides and in vitro using cultures of neuronal-like cells 
or primary neurons (Ledeen and Wu 2015, 2018).  
 
The physiological but also pharmacological properties of GM1 have been studied using 
mainly two approaches: through the manipulation of endogenous GM1 and through the 
application of exogenous GM1 (Ledeen and Wu 2015, 2018; Schengrund 2015). The first 
approach involves the use of endogenous sialidase which locally modifies the ganglioside 
composition of plasma membrane microdomains, reducing the polysialogangliosides in 
favor of the GM1 increase. The administration of the B subunit of cholera toxin (Ctx-B) or 
GM1-specific polyvalent antibodies (of the IgM series), alone or combined, as cross-linking 
agents, was performed in many studies to obtain the clustering of endogenous GM1 
molecules and concomitantly of proteins containing ganglioside binding domains, to 
modulate the activation of downstream pathways. 
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On the other hand, the exogenous administration of GM1 or its derivatives modified due to 
the presence of radioisotopes or photoactivable groups, allowed to study the metabolism of 
ganglioside and the potential lipid-lipid and lipid-proteins interactions among adjacent 
molecules. 
Both approaches have been useful in defining the multiple properties of GM1, which has 
recently been defined as a true factotum of nature (Ledeen and Wu 2015), with results that 
are often consistent but sometimes conflicting given the important differences between the 
two experimental approaches. 
Decades of studies have brought to light ever-increasing evidence of the role of GM1 in 
neuronal differentiation and maturation, in survival and in mechanisms of protection and 
repair of nerve cells. 
 
3.1. GM1 in neuronal differentiation and early development 
It has been well known that ganglioside composition of the nervous system undergoes 
remarkable changes during development. The ganglioside content in the brain drastically 
increases as development proceeds and simultaneously the expression pattern of 
gangliosides shifts from simple gangliosides, such as GM3 and GD3, to complex 
gangliosides, such as GM1, GD1a, GD1b and GT1b in rodents and humans as well (Figure 
I3). 
 
Figure I3: Ganglioside changing in neurodifferentiation. Modification in neuron ganglioside 
pattern during neurodifferentiation reflects the differences in glycosyltransferases and suggests an 
important role of oligosaccharide chains in the process (modified from Yu et al. 2008). Symbols for 
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ganglioside saccharide unites are in accordance with the glycan symbol nomenclature updated in the 
Second Edition of Essentials of Glycobiology (Varky et al. 2009). 
  
This event is accompanied by a change in the expression of genes coding for the 
glycosyltransferases, and mainly the STII (GD3-synthase) which undergoes a 
downregulation during the brain maturation and the GalNacT (GM2/GD2 synthase) which 
is progressively upregulated (Yu et al. 2008).  
The same trend is reproducible in primary cultures of cerebellar neuronal precursors 
obtained from rodents, which undergo a complete maturation process in vitro as already 
reported (Prinetti et al. 2001; Aureli et al. 2011). 
The morphological change is accompanied by modifications in sphingolipids, particularly 
gangliosides, which content increased over other lipids (van Echten and Sandhoff 1988; 
Aureli et al. 2011). Thus, the surface density of gangliosides in the membrane of fully 
differentiated neurons is much higher than in undifferentiated cells. Moreover, the main 
ganglioside in precursor neuron is GD3, whereas GM1, GD1a and more complex 
gangliosides increase during differentiation and maturation with GD1a becoming the most 
represented ganglioside in mature neurons (Figure I4). During in vitro aging of primary 
cerebellar neurons GM1 undergoes impressive reduction resembling what occurs in the 
aging of the entire brain.  
 
Figure I4. Changes in lipid patterns in rat cerebellar granule cells during development and 
aging in vitro. Patterns of radioactive lipids in homogenates obtained from rat cerebellar granule 
cells at the 2nd, 8th and 17th day in culture. Total content of ganglioside increases during 
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development. GD3 represents the most component in immature neurons, whereas during maturation 
complex gangliosides augment (modified from Aureli et al. 2011). 
 
The importance of GM1 in modulating differentiation and neuritogenesis can be seen in 
numerous very earlier studies using neuroblastoma cells and primary neurons where the 
application of GM1 was shown to be directly associated with neuritic outgrowth (Ledeen 
1984; Facci et al. 1984; Skaper et al. 1985; Ledeen et al. 1998). Mouse neuroblastoma cells 
N2a were one of the first and then widely neuron like model used to examine GM1 
neuritogenic properties. The administration of exogenous GM1 to these cells was shown to 
induce neurite sprouting with a mechanism proposed to involve the cell plasma membrane 
(Facci et al. 1984). GM1 was also administered to primary culture of chicken and rat 
embryonic neurons deriving from both central and peripheric nervous system (Skaper et al. 
1985), where it was found to accelerate neurite outgrowth under selected culture conditions. 
In the N2a neuroblastoma cells the same effect was obtained by the application of sialidase 
(Hasegawa et al. 2000) and was inhibited by the concomitant addition of Ctx-B (Wu et al. 
1996). On the contrary, in the N18 neuroblastoma cells the concomitant addition of the toxin 
was necessary to observe neuritogenesis (Masco et al. 1991; Fang et al. 2000). Applied 
sialidase had similar axonogenic effects on spinal neurons (Yang et al. 2006; Mountney et 
al. 2010) even though in these studies the effect was ascribed to concomitant removal of 
polysialogangliosides associated with axon regenerators inhibitors. Da Silva and co-workers 
(Da Silva et al. 2005) demonstrated that in hippocampal neurons, the local enrichment of 
membrane sialidase, by its overexpression, was associated with the locally increase of GM1 
and axon specification, a process dependent on a significant modulation of nerve growth 
factor (NGF) signal. 
In PC12 pheochromocytoma cells, GM1 enhanced NGF-induced differentiation (Ferrari et 
al. 1995) and the latter was found to be subordinated to the presence of membrane GM1 as 
indicated by the abolished NGF responsiveness of PC12 cells following GM1 depletion 
(Mutoh et al. 1998). 
 
3.2. GM1 in neuronal protection and repair 
GM1 ability to protect cells from injuries and insults has been largely examined. 
In N2a neuroblastoma cells the exogenous administration of GM1 protected cells from death 
caused by calcium ionophore application, suggesting the GM1 influence in modulating 
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excitotoxic effects due to massive calcium intracellular elevation. Similar effects have been 
observed in cultures of primary neurons exposed to glutamate. Glutamate represents the 
brain's main neurotransmitters which, through the binding to specific receptors, regulates 
neural communication, memory formation and learning. When neurons are exposed to 
massive glutamate concentration or for prolonged time periods, they are damaged or killed 
due to the excessive levels of calcium ions (Ca2+) entering the cell, a process named 
excitotoxicity.  
Glutamate cytotoxicity was reduced by GM1 in murine cerebellar granule cells (Bachis et 
al. 2002; Sokolova et al. 2014), and in cortical neurons (Park et al. 2016). In the latter study, 
electron spry mass spectrometry detected elevation of endogenous GM1 levels following the 
application of the neurotoxic stimulus to indicate a possible intrinsic defense mechanism 
against neuronal stress. In fact, neurons lacking complex gangliosides due to the ablation of 
β4galnt1 gene (GM2/GD2 synthase) are more susceptible to elevated KCl and glutamate 
excitotoxicity and the application of GM1 rescued their phenotype (Wu et al. 2004).  
GM1 antiperoxidative properties have been also exploited: in PC12 pheochromocytoma 
cells exposed to cytotoxic concentration of H2O2 (Zakharova et al. 2014) and in MPTP-
susceptible cell lines (Saulino et al. 1993; Verma and Schneider 2019) ROS production 
leading to cells death, was prevented by exogenous GM1 application.  
Induction of axonal damage to neurons of the central and peripheric nervous system followed 
by GM1 elevation allowed to examine the surprising reparative and axonogenic abilities of 
GM1. The axonal lesion in primary neurons of the peripheral nervous system leads to the 
local increase of GM1 due to the action of the Neu3 sialidase which starts the regeneration 
process (Kappagantula et al. 2014). This process is essential to induce axonal regrowth. 
Failure to activate sialidase in CNS neurons explains why these neurons are intrinsically 
unable to regenerate, a deficit found to be rescued by the induced sialidase overexpression 
(Rodriguez et al. 2001).  
 
Many reports have examined neuroprotective and neurorestorative properties of GM1 in 
animal models as well as in clinical trials in the contexts of neurological and 
neurodegenerative pathologies. 
Stroke-induced neurological damage is the field where the greatest clinical experience exists 
(Magistretti et al. 2019; Zhang et al. 2019). In several animal model and clinical trials, 
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systemic administration of GM1 was significantly more effective than placebo in improving 
neurological outcomes following a stroke. 
The alteration of the ganglioside organization of the plasma membrane and of sphingolipid 
metabolism has been reported in neurodegenerative diseases and dementias (Piccinini et al. 
2010; Breiden and Sandhoff 2018; Magistretti et al. 2019). This is particularly true for 
progressive neurodegenerative Parkinson's disease (PD), where the continuous death of 
nigro-striatal dopaminergic neurons leads to the onset of the characteristic motor and 
cognitive symptoms of the disease (Zesiewicz 2019, Del Tredici et al. 2002). In this context 
subnormal levels of GM1 have been associated with PD onset both in mouse and in humans 
(Forsayeth and Hadaczek, 2018; Wu et al. 2012). This is due to the recent evidence of lower 
levels of GM1 and expression of ganglioside synthesis genes in the neurons of the substantia 
nigra and occipital cortex of PD patients compared to healthy subjects of the same age 
(Schneider et al. 2018; Hadackzec et al. 2015). Furthermore, the total or partial ablation of 
GM1 ganglioside due to B4galnt1 disruption in genetically modified mice, leads to the 
spontaneous development of the motor impairment and neuropathological lesions 
characteristic of human PD (Wu el al. 2011; Hadackzec et al. 2015).  
Overall, in preclinical models recapitulating the characteristics of PD in vitro and in vivo, 
comprising non-human primates’ PD models (Herrero et al. 1993; Rothbla 1998; Pope-
Coleman 1998), strategies for increasing neuronal GM1 levels have demonstrated their 
effectiveness in preventing stress and nigrostriatal neurons’ death (Schneider et al. 2019, 
2015a; Xu et al. 2014, Hadjiconstantinou et al. 1989). Furthermore, GM1 demonstrated a 
modest but significant efficacy in clinical trials, where PD patients recorded improvements 
in motor and cognitive outcomes compared to the placebo-receiving counterpart (Schneider 
et al. 2010, 2013, 2015b). 
 
The plethora of neurotrophic and neuroprotective effects of GM1 is dependent on the ability 
of the ganglioside to regulate multiple aspects of neuronal development and survival. 
Although the mechanisms underlying these effects are still awaiting to be clearly defined, 
two main molecular aspects are known so far to be strictly regulated by GM1: intracellular 
calcium levels and the neurotrophins-modulated pathways. 
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4. GM1 modulation of Calcium flux 
It is known that calcium represents an important second messenger and its intracellular levels 
are finely regulated to orchestrate the processes of neuronal differentiation and survival. The 
identification of GM1 as a robust calcium flow modulator helped to define the molecular 
basis of the GM1 spectrum of action (Ledeen and Wu 2018). 
 
4.1. GM1 influence on calcium influx 
Elevation of GM1 on the surface of N2a and certain other neuroblastoma cells by exogenous 
sialidase induced calcium influx via channel identified as low-threshold voltage dependent 
T-type (Wu and Ledeen 1991; Fang et al. 2000). A similar phenomenon was observed in 
primary cultures of hippocampal neurons, where GM1-mediated axonogenesis was 
accompanied by local calcium influx (Rodriguez et al. 2001). 
The regeneration of injured peripheral nerve promoted by GM1 elevation due to local Neu3-
sialidase action in the membrane, is associated to the increase in calcium influx 
(Kappagantula et al. 2014). Such activation failed to occur in injured retinal neurons of 
central nervous system despite the presence of Neu3 in the tissue. This was suggested to 
account for the failure of injured central nervous system axons to regenerate in contrast to 
the ability of peripheric nervous system axons to do so. Also the use of the Ctx-B as GM1-
crossilinking agent was shown to induce calcium influx in both central (Wu et al. 1996) and 
peripheric neurons (Milani et al. 1992). 
An alternative mechanism of intracellular calcium regulation by GM1 involves the transient 
receptor potential channel 5 (TRPC5), observed by the employment of crosslinking agents 
on primary central and peripheric neurons. In these studies, a co-crosslinking with proteins 
associated with GM1 occurred, such as integrin heterodimer α5β1, which in turn activated 
an adhesion kinase and the downstream pathway leading to the opening of the TRPC5 
channel (Wang et al. 2009). 
 
4.2 GM1 influence on calcium efflux  
The finding that GM1 protected neurons from the toxic effects induced by glutamate and the 
calcium ionophore (paragraph above) suggested a regulation of intracellular calcium 
homeostasis including also its extrusion. 
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Calcium efflux from the neuronal cytoplasm was found to be under GM1 regulation at least 
via two mechanisms: plasma membrane calcium ATPase (PMCA) and Na+/Ca2+ exchanger 
(NCX). PMCA accounts for the high affinity low capacity system representing the major 
system regulating calcium efflux while NCX is the opposite. In neurons membrane PMCA 
isoform 2 is the most expressed (Burette et al. 2003) and was found to be slightly inhibited 
by GM1 (Zhao et al. 2004). On the other hand, NCX was found to be associated with and 
regulated by GM1 (Xie et al. 2002). The presence of the NCX associated with GM1 in the 
nuclear envelope has suggested a mechanism of regulation of nucleoplasmic calcium levels. 
The NCX/GM1 complex mediates the transfer of calcium from the nucleoplasm to the 
luminal space of the nuclear envelope, which is continuous with the lumen of the 
endoplasmic reticulum, serving as a protection mechanism for the nucleus against the action 
of enzymes activated by the increase in calcium levels (Wu et al. 2009). 
 
A schematic summary of the regulation of calcium flows by GM1 at various cellular levels 
is shown in the Figure I5. 
 
 
Figure I5: Summery of GM1 influence on regulation of calcium flux. GM1 can interact directly 
or indirectly with different proteins responsible to mediate influx or efflux of Ca2+ across cell 
membranes. NCX, Na+/Ca2+ exchanger; TRPC5, transient receptor potential channel 5; PMCA, 
plasma membrane Ca2+-ATPase pump; SERCA, sarco/endoplasmic Ca2+-ATPase pump; PTP, IP3-
R, inositol-3-phosphate receptor; PTP, permeability transition pore (Ledeen and Wu 2015). 
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5. GM1 modulation of neurotrophic signal  
 
5.1. Neurotrophins and neurotrophic factors receptors 
Neurotrophic factors, such as the family of neurotrophins, are recognized for their role in 
neuronal differentiation, survival and maturation. The long-term survival of neurons is due 
to continuous support from neurotrophins, and the progressive decrease in support derived 
from the underlying signaling contributes to neurodegeneration. The neurotrophin family 
includes nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), 
neurotrophin (NT)-3, NT-4/5 and NT-6. These factors act by binding to transmembrane 
tyrosine kinase receptors (Trk) and p75 neurotrophin receptor (p75NTR), promoting 
receptor activation (Huang, 2001). In particular, NGF binds to TrkA; BDNF and NT 4/5 
bind to TrkB; NT-3 primarily activates TrkC but can also bind TrkA and B. p75NTR binds 
to all neurotrophins with a lower affinity then the others Trk. Neurotrophins’ binding to Trk 
induces receptor tyrosine kinase dimerization and autophosphorylation, therefore initiating 
a complex cascade of signal transduction events. Tyrosine phosphorylated Trk binds to Shc, 
phospholipase C and phosphatidyl inositol 3-kinase (PI3K) through SH2 domains resulting 
in their phosphorylation and subsequent activation of intracellular signaling pathways and 
transcription factors regulating gene expression (Kaplan and Stephens 1994; Klesse and 
Parada 1999).These pathways transduce signals independently, but also can converge on the 
same downstream effector. Stimulation of a variety of tyrosine kinase receptors leads to a 
rapid elevation of the enzymatic activity of a family of structurally related serine–threonine 
kinases, known as mitogen-activated protein kinases (MAPKs), which convert extracellular 
stimuli to intracellular signals that control gene expression (Schaeffer and Weber 1999). 
 
Members of other neurotrophic factor families have also been shown to activate tyrosine 
kinases. These include glial-cell-line-derived neurotrophic factor (GDNF) family ligands 
(GFLs). GFLs bind to specific GDNF family receptor α (GFRα) proteins, all of which form 
receptor complexes and signal through the RET receptor tyrosine kinase. Among all 
components of the family, GDNF has been largely studied for its importance in regulating 
the survival of dopaminergic neurons (Sariola et al. 2003). GDNF displays highest affinity 
for GFRα1. The receptor complex GDNF–GFRα1 binds to the extracellular domain of RET 
receptor modulating various intracellular signaling cascades, comprising PLC, PI3K and 
MAPK pathways sustaining differentiation, maturation and survival of neurons.  
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A summary of the intracellular pathways activated by neurotrophic receptors is outlined in 
Figure I6 
 
 
Figure I6. Schematic illustration of neurotrophins’ signaling sustaining neuron differentiation, 
growth and survival. NT = neurotrophins, BDNF = brain-derived neurotrophic factor, TRK = 
tyrosine receptor kinase, GDNF = glial-derived neurotrophic factor, PLC = phospholipase C, RAS = 
Ras proteins, GRB = growth factor receptor-bound protein 2, PIK3 = phosphatidylinositol-4,5-
bisphosphate 3-kinase, AKT =AKT serine/threonine–protein kinases, FOXO = The forkhead box O 
transcription factor, PKC = protein kinase C, CREB= the cAMP-responsive element-binding protein 
(modified from Kashyap et al. 2018). 
 
5.2. GM1 influence on neurotrophic receptors 
Neurotrophins and their receptors have been shown to be GM1 substrates, contributing to 
explain the neurotrophic and protective effects of the ganglioside (Ferrari et al. 1995; Mutoh 
et al. 1995; Farooqui et al. 1997; Bachis et al. 2002). Earlier studies demonstrated that GM1 
was able to activate TrkA receptor in different cell lines (Mutoh et al. 1995; Rabin et al. 
1995) and primary neurons (Da Silva et al. 2005), suggesting GM1 may mimic NGF activity 
in inducing neuronal differentiation and neuritogenesis. Moreover, in injured peripheric 
neurons the local increase of GM1 level due to the activation of Neu3 sialidase is 
accompanied by ERK1/2 activation which drives axonogenesis. (Kappagantula et al. 2014). 
The application of GM1 to ex-vivo cultures of striatum, frontal cortex and hippocampus of 
adult rats resulted in the activation of Trks and ERKs, and the effect was confirmed by in 
vivo intraventricular injection of the ganglioside (Duchemin et al. 2002). 
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Also the protective role of GM1 has been found depending on TrkA activation (Sokolova et 
al. 2014) coupled to ERK1/2 and Akt downstream pathways (Zakharova et al. 2014). 
In addition to what found about TrkA receptor, TrkB appeared to be modulated by the 
presence of GM1 in the plasma membrane of cultured neurons (Pitto et al. 1998; Bachis et 
al. 2002).  
A similar finding was reported for the GDNF receptor. GM1 was shown to associate with 
the GDNF receptor complex comprised of Ret, the tyrosine kinase component, and GFRα, a 
GPI-anchored coreceptor; Ret association with GFRα was severely impaired in neurons 
totally or even partially devoid of GM1 (Hadaczek et al. 2015). Also the downstream MAPK 
phosphorylation was found lower in GM1 deficient neurons, which appeared to be restored 
by the administration of a GM1-analogue. 
6. GM1-oligosaccharide as the bioactive portion of GM1 
Despite the many evidence about the neurotrophic and neuroprotective properties of GM1, 
both from a physiological and pharmacological point of view and although some molecular 
partners of GM1 have been identified, the mechanism of action underlying its properties 
remained elusive.  
Significant studies were carried out using GM1 derivatives keeping the same oligosaccharide 
structure, with the replacement of the long chain fatty acid of ceramide by a shorter group, 
such as acetylene (LIGA 4) (Manev et al. 1990) or dichloroacetylene (LIGA20) (Costa et al. 
1993; Kharlamov et al. 1993; Saito et al. 1999; Rabin et al. 2002), represented in Figure. I7.  
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Figure I7. Semisynthetic GM1 derivatives chemical structures. A: LIGA 4; B: LIGA 20 
 
In these studies, GM1 derivatives have proved to exert similar effects to those of GM1 with 
the involvement of Trks and RET receptors. Their remarkable difference from the parent 
compound resides in the incremented membrane permeability and, therefore, enhanced 
capability to penetrate the blood–brain barrier (BBB) and neuronal plasma membrane. 
Nevertheless, it was evident that the structure of the ceramide did not seem indispensable 
for GM1 to exercise its properties. 
 
Furthermore, the above mentioned evidence of neurodifferentiating and protective effects 
observed deriving from  the manipulation of endogenous GM1 following the modulation of 
the activity of membrane sialidase Neur3, suggests an important influence of the 
oligosaccharide chain in the fine-tuning of the processes beginning at the level of plasma 
membranes. 
 
However, the pioneering work of Schengrund and collaborators (Shengrund and Proudy 
1988) showed much earlier that the GM1 oligosaccharide (oligoGM1) alone maintained the 
neuritogenic properties of GM1 in neuroblastoma cells S20Y. 
More recent studies have investigated the oligoGM1 differentiative properties, confirming 
its neuritogenic potential in N2a murine neuroblastoma cells (Chiricozzi et al. 2017). In this 
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study the addition of oligoGM1 in the culture medium induced the emission of neuritic 
prolongations and the elevation of the Neurofilament proteins analogously to what was 
observed administering the entire GM1 as shown in Figure I8. 
 
 
Figure I8. Neurodifferentiation of N2a cells induced by GM1 and oligoGM1. OligoGM1 induced 
neuritogenesis is comparable to the one induced by GM1 on N2a neuroblastoma cells (Chiricozzi et 
al. 2017).  
 
Incubation with sugar derivatives, Gg4, II3Neu5Ac-Gg3, sialyllactose, galactose, or sialic 
acid was performed in order to clarify the minimal structure required to promote neurite 
elongation. None of these compounds was found able to induce cell morphological changes. 
Interestingly, the administration of a GM1-oligosaccharide derivative containing a α-fucose 
in the second position of the external galactose, was shown to induce neurite sprouting and 
reduction of cell proliferation in a similar way as II3Neu5Ac-Gg4 . This result suggested that 
the β-Gal-(1-3)-β-GalNAc-(1-4)-[α-Neu5Ac-(2-3)]-β-Gal-(1-4)-Glc represented the 
minimal structure required by the saccharide to exert its neuronal function and the addition 
of an α-fucose at position 2 of the external galactose was irrelevant for the process. 
In time-course experiments employing a radiolabeled form of oligoGM1, the researchers 
found no trace of radioactivity inside the cells, concluding that the morphological effect 
depended on an action at the level of the cellular surface (Chiricozzi et al. 2017). 
Investigating the molecular pathway promoted by oligoGM1 in more detail, the researchers 
found that the sugar induced an increase in TrkA receptor phosphorylation on tyrosine 490, 
accompanied by an increase in MAPK ERK1/2 activation. GM1 induced the same pathway 
at a comparable extent and a specific TrkA inhibitor abolished oligoGM1 induced 
neuritogenesis (Scheme in Figure I9) 
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Figure I9. Scheme of the proposed mechanism underling GM1 neuritogenic effect in N2a. GM1 
enhances TrkA phosphorylation on tyr490, throughout its oligosaccharide component. TrkA 
activation induces MAPK differentiative pathway. ERK, extracellular signal-regulated protein 
kinases 1 and 2; Grb2, growth factor receptor-bound protein 2; Gab1, Grb2-associated binder-1; 
RAS, GTP-binding protein; RAF, serine/ threonine kinase; SHC, transforming protein 1; SOS, son 
of sevenless (Chiricozzi et al. 2017). 
 
By photolabeling experiments performed with a nitrophenylazide containing oligoGM1, 
labeled with tritium, a direct interaction between the GM1 oligosaccharide and the 
extracellular domain of TrkA receptor was shown (Figure I10).  
This discovery demonstrated for the first time a direct association between the NGF receptor 
and one specific portion of GM1, i.e. the oligosaccharide. 
This evidence was confirmed in the subsequent study (Figure I10) that employed two 
modified forms of radiolabeled GM1: one carrying a photo-activatable phenylazide group 
associated with the oligosaccharide chain, and the other one carrying the same group within 
the lipid portion (Chiricozzi et al. 2019a). After administration of these two derivatives to 
the N2a, the cells were irradiated with UV light. The proteins were then extracted, separated 
by SDS-PAGE and transferred onto a PVDF membrane. The membrane was subjected to 
autoradiography and subsequently incubated with TrkA specific antibody. The overlapping 
between the radioactive and the chemiluminescent signals was obtained only by using the 
radiolabeled-GM1 derivative containing the photoactivable group inserted in the 
oligosaccharide head. This finding clearly indicated that the interaction between TrkA and 
ganglioside GM1 occurred outside the cell at the level of the oligosaccharide. 
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Figure I10. Interaction between TrkA and GM1 occurs at the level of GM1-oligosaccharide in 
N2a cells. Radiolabel derivative of GM1 carrying the photoactivable group, represented by the green 
star in the symbolic representation, were administered to cells. UV light was used to induce 
crosslinking between GM1-derivates and surrounding molecules. After radiography of cell protein 
pattern and TrkA immunoblotting, overlapping between radio-signal and chemiluminescent signal 
was only found with oligoGM1 and GM1 carrying photoactive group on the oligosaccharide 
(Chiricozzi et al. 2017, 2019a) 
 
Accordingly, molecular docking analyses confirmed that GM1 oligosaccharide binds the 
TrkA-NGF complex significantly reducing the free energy of association, acting as a bridge 
able to increase and stabilize the TrkA-NGF molecular interactions (Figure I11) 
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Figure I11. Modeling the interaction between NGF-TrkA complex and oligoGM1. TrkA in 
orange ribbons; two NGF molecules: one in cyan ribbons and one in magenta ribbons. OligoGM1 is 
represented in sticks, with blue color for carbon atoms and red color for oxygen atoms. Van der 
Waals interaction surface between oligoGM1and proteins is represented as a white mesh map 
(Chiricozzi et al. 2017). 
 
These studies are beginning to shed new light on the mechanism of action of the GM1 
neurotrophic effects, identifying in its oligosaccharide component the portion responsible 
for its neuritogenic properties, at least in neuroblastoma cells. 
Therefore, in the presence of physio-pathological alterations of the membrane ganglioside 
composition, it is becoming important to focus attention on the contribution given by the 
change in the oligosaccharide composition. In this perspective, the increase in GM1 levels, 
for instance, locally enriches the glycocalyx of oligoGM1 molecules which are likely 
responsible for downstream biosignaling. 
The question remains whether in primary neurons, the oligosaccharide is able to exert a 
similar effect, going to replace the role of the whole ganglioside.
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The neurotrophic properties of GM1 have been extensively studied both in vitro and in vivo. 
Regardless of the approach used, the conclusions of all the studies led to the assertion that 
the increase in GM1 content at the plasma membrane level favors neuronal differentiation, 
maturation and survival. Despite this certainty, the molecular basis of the mechanism of 
action of GM1 is currently unclear. Even the portion indispensable of the biological role of 
GM1 was obscure until two years ago, when the discovery that GM1 oligosaccharide 
corresponds to the bioactive portion of GM1, which alone exerts the same differentiating 
effect as the entire GM1 in N2a neuroblastoma cells, allowed to shed new light in this field 
(Chiricozzi et al. 2017).  
Often the bio-active properties of amphiphilic lipids such as gangliosides have been 
attributed to the hydrophobic component which, through alteration of membrane physical 
properties, or through the direct interaction with membrane proteins, could influence 
intracellular signaling (Chiricozzi et al. 2015; Loberto et al. 2003). Aside of the ceramide, 
the hydrophilic head of glycolipids, with a specific order and composition of saccharide 
units, can regulate the functioning and activation of membrane proteins and therefore 
modulate entire signal transduction pathways. In the case of GM1, its oligosaccharide 
portion was found to interact directly with the extracellular portion of TrkA, the specific 
receptor for NGF, stabilizing the complex between the ligand and the receptor and therefore 
favoring TrkA activation. The increase in TrkA phosphorylation was associated with the 
elevation of the MAP kinases activity responsible for blocking N2a proliferation and 
induction of differentiation. 
The raising question was whether GM1 oligosaccharide could influence neuronal 
differentiation and development in a more physiological context. The aim of the doctoral 
project was to evaluate the effects of oligoGM1 in neuronal progenitors both from a 
morphological and a molecular point of view, trying to define the mechanism by which GM1 
molecule exercises its neurotrophic role. 
For this purpose, primary cultures of cerebellar granular neurons were used. These cells 
differentiate and mature in vitro allowing the study of physiopatological processes such as 
neuronal development, maturation and aging. Furthermore, these cells have been widely 
used for the study of the lipid pattern and its dynamics during neuronal aging. More 
importantly, it has been shown that in granular cells, GM1 is able to influence the activity 
of Trk receptors (Rabin et al. 2002). In the present study, the oligosaccharide chain of GM1 
was employed with the purpose to provide knowledge regarding the mechanism by which 
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the specific sugar code of GM1 influences neuronal differentiation through the modulation 
of plasma membrane signaling. 
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Materials 
Commercial chemicals were of the highest purity available, common solvents were distilled 
before use and water was doubly distilled in a glass apparatus. 
Phosphate buffered saline (PBS), paraformaldehyde (PFA), RNAase-free water, sodium 
orthovanadate (Na3VO4), phenylmethanesulfonyl fluoride (PMSF), aprotinin, and protease 
inhibitor cocktail (IP), (Ctx-B-HPR), o-phenylenediamine tablets, H2O2, bovine serum 
albumin (BSA), donkey serum and rabbit polyclonal anti-GADPH (RRID:AB_796208) 
antibody were from Sigma-Aldrich (St. Louis, MO, USA). Fetal Bovine Serum (FBS), L-
Glutamine and penicillin/streptomycin (10.000 Units/ml) were from EuroClone (Paignton, 
UK). Rabbit anti-TrkA (RRID: AB_10695253), rabbit anti–extracellular signal‐regulated 
protein kinases 1 and 2 (ERK1/2) (RRID: AB_390779), rabbit anti-phospho-ERK (p-
ERK1/2, Thr202/Tyr204) (RRID: AB_2315112), goat anti-rabbit IgG (RRID: 
AB_2099233), mouse anti-β3-tubulin (RRID:AB_1904176), rabbit anti-phospho-Src 
(RRID:AB_331697), rabbit anti-Synapsin (AB_2200102) antibodies were from Cell 
Signaling Technology (Danvers, MA, USA). Mouse anti-phospho-TrkA (Tyr490) 
(RRID:AB_628399) antibody was from Santa Cruz Biotechnology (Heidelberg, Germany). 
Mouse anti-neuroglycan C (RRID not available), mouse anti-phospho-FAK (Tyr 397) 
(RRID:AB_399286), mouse anti-FAK (RRID:AB_397494) was from Becton Dickinson. 
Chemiluminescent kit for western blot was from Cyanagen (Bologna, Italy). Rabbit anti-pan 
Neurofilament (NF) antibody (RRID: AB_10539699) was from Biomol International 
(Plymouth Meeting, PA, USA). Neurobasal A medium, B27 Supplement, 4',5-Diamidina-2-
phenylindole (DAPI), DNase I, SuperScript™ III First-Strand Synthesis System, 
Oligo(dT)20 Primer and SYBER Green Master Mix were from Thermo Fischer Scientific 
(Waltham, MA, USA). Ultima gold was from Perkin Elmer (Waltham, MA, USA). 4 –20% 
Mini -PROTEAN® TGX™ Precast Protein Gels, Turbo Polyvinylidene difluoride (PVDF) 
Mini -Midi membrane and DC ™ protein assay kit were from BioRad (Hercules, CA, USA). 
High performance thin layer chromatography (hpTLC) plate and Triton X -100 were from 
Merk Millipore (Frankfurten, Germany).  
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Methods 
1. Chemical synthesis and preparation of gangliosides GM1 and GD1a and their 
oligosaccharides  
1.1 Gangliosides’ purification 
GM1 and GD1a gangliosides were purified from the total ganglioside mixture extracted from 
fresh pig brains collected at the slaughterhouse of the Galbani company (Melzo, Italy), 
according to the procedure developed previously (Tettamanti et al. 1973). High amount of 
GM1 was obtained by the sialidase treatment of the total pig brain ganglioside mixture. This 
simplified the purification process as the major part of polysialogangliosides were 
transformed into GM1 (Acquotti et al. 1990). The ganglioside mixture, 5 g as sialic acid, 
was dissolved in prewarmed (36°C) 500 mL of 0.05 M sodium acetate, 1 mM CaCl2 buffer, 
pH 5.5. Vibrio cholerae sialidase (1 unit) was added to the solution every 12 h. Incubation 
at 36°C and magnetic stirring was maintained for two days, and the solution dialyzed at 23°C 
for 4 days against 10 L of water changed 5 times a day. The sialidase treated ganglioside 
mixture was subjected to 150 cm x 2 cm silica gel 100 column chromatography equilibrated 
and eluted with chloroform -methanol -water, 60:35:5 by vol. The fractions containing GM1, 
identified by TLC, were pooled, dried and submitted to a further column chromatographic 
purification using the above experimental conditions. Fractions containing pure GM1 were 
collected and dried. The residue was dissolved in chloroform-methanol (2:1 v/v) and 
precipitated by adding 4 volumes of cold acetone. After centrifugation (15.000 x g) the GM1 
pellet was separated from the acetone, dried, dissolved in 50 mL of deionized water and 
lyophilized giving 1350 mg of white powder which was stored at -20°C.  
1.2 Radiolabeled GM1 
GM1 containing tritium at position 6 of external galactose was prepared by enzymatic 
oxidation with galactose oxidase followed by reduction with sodium boro [3H]hydride 
(Sonnino et al. 1996) Figure M1.  
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Figure M1: [Gal-6-3H]GM1 structure. 
 
1.3 Gangliosides’ oligosaccharides 
The oligosaccharides II3Neu5Ac-Gg4, II3Neu5Ac-[3H]Gg4 and IV3AcII3Neu5Ac-Gg4 were 
prepared by ozonolysis followed by alkaline degradation (Wiegandt and Bucking 1970), 
from GM1, [3H]GM1 and GD1a respectively (Figure M2). Briefly, GM1, [3H]GM1 or GD1a 
was dissolved in methanol and slowly saturated with ozone at 23°C. The solvent was then 
evaporated under vacuum and the residue brought immediately to pH 10.5-11.0 by addition 
of triethylamine. After solvent evaporation, GM1 and GD1a oligosaccharides were purified 
by flash chromatography using chloroform/methanol/2-propanol/water 60:35:5:5 v/v/v/v as 
eluent. Oligosaccharides were dissolved in methanol and stored at 4°C.  
Altogether, NMR, MS, HPTLC and autoradiographic analyses showed a homogeneity over 
99% for all the prepared gangliosides and oligosaccharides. 
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Figure M2: Chemical synthesis of oligoGM1 and [Gal-6-3H]-oligoGM1 and oligoGD1a. 
Ozone-alkali fragmentation procedure was used to obtain desphingosino-gangliosides. 
Ozonolysis organic reaction cleaved unsaturated bond between sphingosine 4 and 5 carbons. 
Subsequently, the alkaline degradation with triethylamine released the oligosaccharide chain 
form the residue. 
 
 
2. Primary culture of cerebellar granule neurons (CGN) 
Pregnant C57BL/6J mice were provided by Charles River Laboratories International (project 
numbers 946/2017-PR and 255/2019-PR). All animal procedures were approved by the 
Ethics Committee of the University of Milano, Italy and were performed in accordance with 
the National Institute of Health Guide for the Care and Use of Laboratory Animals (Directive 
2010/63/EU). CGN were prepared as previously described (Bilimoria, 2008) with some 
modifications. Briefly CGN were dissociated from pooled cerebella of 5-day-old pups by 
mechanic trituration with blade (35 plus 35 times in perpendicular directions), followed by 
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incubation with 1% (W/V) Trypsin plus 0,1% (w/v) DNase I in PBS (1 mL every 5 cerebella) 
for 3.5 min at 23°C. The reaction was stopped by centrifugation of the cell mixture at 1000 
x g for 10 sec and the supernatant was removed. The cell pellet was resuspended in the 
solution of 0.04% (w/v) Trypsin inhibitor plus 0.1% DNase I in PBS (1 mL every 5 
cerebella). The cells were definitively dissociated by repeated passages through descending 
caliber glass Pasteur. 
The reaction solution was removed by centrifugation and the cells were washed with 0.2% 
glucose in PBS before being resuspended in Neurobasal A medium containing 25 mM KCl, 
1% B27 Supplement, 1% L-Glutamine and 1% penicillin/streptomycin. Cells were counted 
with a Burker chamber, plated at a density of 315000 cells/ cm2 on plastic or glass coverslips 
precoated with poly-L-lysine (10 µg/mL for 2 h at 37°C) and maintained at 37 °C in a 
humidified atmosphere of 95% air/5% CO2.  
As shown in Figure M3, CGN maturation process consists in a first phase of cell aggregation 
followed by neurite elongation up to the formation of a neural network in three days and 
becoming adult neurons in 1 week.  
 
 
Figure M3. Differentiation and maturation of the CGN. Representative images of phase-contrast 
optical microscopy of CGNs dissociated from cerebellum tissue of P5 mice and grown in vitro. 100X 
magnification. a) 1 DIV; b) 2 DIV; c) 3 DIV; d) 7 DIV; e) 14 DIV; f) 20 DIV. DIV = Day In Vitro. 
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2.1 CGN treatment 
Gangliosides and oligosaccharides were solubilized in methanol. To perform cell treatment, 
they were dried under nitrogen gas and dissolved in culture medium by vortex agitation and 
sonication in water bath 3 times for 30 sec. Solubilized gangliosides and saccharides were 
administered to cells during plating at the final concentration of 50 µM (Chiricozzi et al. 
2017). Control cells were incubated under the same experimental condition but omitting any 
other addition.  
 
3. Morphological analysis 
CGN treated with gangliosides or oligosaccharides (50 μM) were observed over times by 
contrast phase microscopy with Olympus BX50 microscope (Olympus, Tokyo, Japan), with 
a 10X objective to final magnification of 100X. At least 10 random fields from each well 
were acquired from 8 different experiments. 
Neuronal migration and motility were examined by live cell analysis. CGN seeded in 
Corning 6 well plates were immediately incubated in the IncuCyte® S3 system (Sartorius 
Stedim Biotech) to the automated live cell recording in phase contrast with 10X objective. 
16 fields per well were randomly acquired every 2 h up to 24 h, in triplicate, in three different 
experiments. The analysis of the dynamics of neuronal clusters was performed automatically 
by the IncuCyte® S3 Software (V2018A, Sartorius Stedim Biotech), setting a segmentation 
index equal to 0.2. In this way the program identified objects related to clusters of neuronal 
cells in each frame, highlighting them in yellow. Finally, the count of the area occupied by 
the objects defined as clusters with respect to the area of each field returned the percentage 
of neuronal clusters’ confluence for each frame. 
 
4. Immunofluorescence analysis 
CGN were seeded onto glass coverslip for 24 h or 48 h in the presence or in the absence of 
50 µM oligoGM1. Then cells were fixed in 4% PFA in PBS for 20 min at 23°C. Cells were 
permeabilized with 0.1% Triton X‐100 in PBS for 30 min and then treated with a blocking 
solution containing 10% donkey serum in PBS for 1 h at 23°C. Cells were incubated with 
rabbit polyclonal antibody anti‐Neurofilament (NF) for 2 h at 23°C. Cells were then rinsed 
in PBS and incubated 1 h with secondary anti‐rabbit FITC‐conjugated antibody. Nuclei were 
then detected by reaction with DAPI reagent 10 min at 23°C. Fluorescence microscopy was 
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carried out using an Olympus U‐RFL‐T EPI Fluorescence Microscope (Olympus, Tokyo, 
Japan) and the images’ processing was performed with ImageJ software (ImageJ, NIH 
http://rsb.info.nih.gov/ij/). At least 10 fields for each condition were acquired.  
 
5. Fate of oligoGM1 added to the cells 
Fate of oligoGM1 administered to CGN was determined using tritium‐labeled oligoGM1 on 
the external galactose saccharide (β-[6-3H]Gal-(1-3)-β-GalNAc-(1-4)-[α-Neu5Ac-(2-3)]-β-
Gal-(1-4)-Glc). CGN were incubated in the presence of 50 μM [3H]oligoGM1 for different 
times. Then the medium was removed and the following treatments were performed 
sequentially: (i) cells were washed three times with 10% FBS‐medium to remove and collect 
the fraction of oligoGM1 weakly associated to the cells — serum removable fraction; (ii) 
cells were incubated with 0.1% trypsin solution for 1 min to remove the fraction of the 
oligoGM1 strongly linked to extracellular domain of plasma membrane proteins — trypsin 
removable fraction; (iii) cells were lysed in order to obtain the fraction of oligoGM1 
internalized by the neurons — trypsin stable fraction. The radioactivity associated to each 
fraction was determined by liquid scintillation counting. The procedure was established 
previously to determine the fate of gangliosides and GM1 oligosaccharide administered to 
cells in culture (Chigorno et al. 1985; Chiricozzi et al. 2017). 
 
6. Protein determination  
Protein concentration of samples was assessed using a DC™ protein assay kit according to 
manufacturer’s instructions, using BSA as standard. 
 
7. Protein analysis  
CGN grown in the presence or in the absence of oligoGM1 (50 μM) were washed twice with 
1 mM Na3VO4 and lysed with 1 mM Na3VO4, 1 mM PMSF, 2% (v/v) aprotinin, and 1% 
(v/v) IP in cold PBS. Equal amounts of proteins were denatured, separated on 4-20% precast 
polyacrylamide gels, and transferred to PVDF membranes using the Trans -Blot® Turbo™ 
Transfer System (Bio -Rad). The presence of Neuroglycan C, β3-Tubulin, Synapsine I, FAK, 
P-FAK (tyr 397), Src, P-Src (tyr 416), TrkA, P‐TrkA (tyr 490), ERK1/2 and P‐ERK1/2 
(Thr202/Tyr204) was determined by specific primary antibodies, followed by reaction with 
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secondary HPR‐conjugated antibodies. GADPH was used as loading control. The data 
acquisition and analysis were performed using Alliance Uvitec (Eppendorf, Germany). 
 
8. mRNA analysis 
CGN grown in the presence or in the absence of oligoGM1 were lysed with TRIzol RNA 
Isolation Reagent (Thermofisher) followed by phase separation in chloroform and RNA 
isolation with isopropanol following manufacturer’s instructions. RNA pellet was air dried 
and solubilized in 20 µL RNAase-free water. RNA yield was determined by The 
NanoDrop® ND-1000 UV-Vis Spectrophotometer (Thermofisher). Following reaction with 
DNAse I (2,73 U/µL) for 15 min at 23°C, 1 µg RNA was reverse transcribed by Superscript 
III First-Strand Synthesis System kit using Oligo-dT20 following manufacturer’s 
instructions.  
The relative transcript level determination was performed by quantitative PCR in triplicate 
using SYBR Green PCR Master Mix (Applied Biosystems). Primers pairs used are: Synapsin 
I (fwd: 5’- AGCTCAACAAATCCCAGTCTCT-3’, rv: 5’- 
CGGATGGTCTCAGCTTTCAC- 3’); Neuroglycan C (fwd: 5’- 
TCTTCCTCACATCTCCCCTTTT - 3’, rv: 5’- TCTTCAAAGCTGTTTGGTGACTG - 3’); 
β3-Tubulin (fwd: 5’- TAGACCCCAGCGGCAACTAT - 3’, rv: 5’- 
GTTCCAGGTTCCAAGTCCACC - 3’). The housekeeping gene used as endogenous 
normalizer was Gadph (fwd: 5’- AGGTCGGTGTGAACGGATTTG – 3’, rv: 5’- 
TGTAGACCATGTAGTTGAGGTCA - 3’). Thermocycling conditions were 10 min at 
95°C, then 40 cycles of 15 sec at 95°C and 1 min at 60°C. The program was performed by 
QuantStudio 5 Real-Time PCR System (Applied Biosystem). The obtained Ct values were 
normalized to the respective value of Gadph and expressed as a function of the control 
condition (untreated neurons) using the comparative Ct method (ΔΔCt), considering PCR 
efficiency (Livak et al. 2001). 
 
9. Gangliosides analysis  
For the analysis of endogenous ganglioside pattern, neurons treated or not with 50 μM 
oligoGM1 were lysed in water and subjected to lyophilization. Total lipids were extracted 
from lyophilized cells with the solvent mixture of chloroform/methanol/ water, 2:1:0.1, by 
vol, followed by a second and third extraction with chloroform/methanol, 2:1 by vol 
(Chiricozzi et al. 2014; Samarani et al. 2018; Malekkou et al. 2018). The total lipid extracts 
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were then subjected to a two phase partitioning, by adding 20% of water to the lipid extract 
resulting in the separation of an aqueous phase containing gangliosides and an organic phase 
containing all other lipids (Folch et al. 1957). Following a dialysis step to remove salts, 
gangliosides contained in the dialyzes aqueous phase, corresponding to 700 µg of proteins, 
were separated by a first run in chloroform/methanol 2/1 (v/v), followed by a second run in 
chloroform/methanol/ 0.2% aqueous calcium chloride 50/42/11 (v/v/v). Following solvent 
evaporation, gangliosides were revealed by specific detection spraying with Anisaldehyde 
reagent, and heating at 120° C for 15 min; co-migration with standards allowed the 
identification of gangliosides species. The relative amount of each ganglioside, was 
determined by densitometry using ImageJ software (NIH, Bethesda, USA; 
http://rsbweb.nih.gov/ij/).  
9.1 Time course analysis of gangliosides by Ctx-B-HRP staining 
The expression of complex gangliosides over time was followed by the detection technique 
which uses the subunit B of cholera toxin conjugated to peroxidase. This subunit binds GM1 
specifically and has often been used to identify GM1 in cell cultures and on TLC plates after 
separation of gangliosides, together with more complex gangliosides following the reaction 
with sialidase (Chiricozzi et al. 2018). In this way, the levels of GM1, GD1a, GD1b and 
GT1b could be analyzed. Ctx-B-HRP staining is an extremely sensitive technique, capable 
of identifying and quantifying even a few picomoles of GM1 ganglioside (Wu et al. 1988).  
To specifically detect GM1, GD1a, GD1b and GT1b gangliosides’ content in CGN treated 
or not with oligoGM1, gangliosides of aqueous phase, equivalent to 15 µg of proteins, and 
standard of gangliosides, equivalent to 10 pmol, were spotted on TLC plate and subjected to 
a first-run in chloroform/methanol 2/1 (v/v) followed by a second run in 
chloroform/methanol/0.2% aqueous calcium chloride 50/42/11 (v/v/v). Following solvent 
evaporation, the plate was treated for 30 sec with a solution of 0.2% polyisobutylmethacrilate 
in hexane (v/v) for three times and air dried for 1 h. After 30 min of pre-incubation at 23°C 
in 1M Tris-HCl pH 8, 0.14 M NaCl containing 1% BSA (w/v), the plate was subjected to 
the reaction with sialidase diluted at 0.12 U/mL in 0.05 M acetate buffer (pH 5.4), 4 mM 
CaCl2, for 2 h at 37°C. Then the plate was overlaid with Ctx-B subunit-HPR conjugated (40 
ng) in 1% BSA (w/v) at 23°C for 1 h. After washing 3 times with PBS , plates were 
developed with o-phenylenediamine (1 tablet in 12.8 mL of citrate-phosphate buffer 0.05 M 
(pH 5) and 17 μL of H2O2. The amount of GM1, GD1a, GD1b and GT1b was calculated by 
comparing the intensity of the spot in the different samples with respect to that of the 
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standard equivalent to 10 pmol by densitometry using ImageJ software (NIH, Bethesda, 
USA; http://rsbweb.nih.gov/ij/). 
 
10. Statistical analysis 
Data are expressed as mean ± SEM and were analyzed for significance by Student's t‐test or 
two‐way ANOVA test. The analysis was performed with Prism software (GraphPad 
Software, Inc. La Jolla, CA, USA). 
 
11. Other analytical methods 
NMR spectra were recorded with a Bruker AVANCE-500 spectrometer at a sample 
temperature of 298 K. NMR spectra were recorded in CDCl3 or CD3OD and calibrate using 
the TMS signal as internal reference. Mass spectrometric analysis were performed in positive 
or negative ESI-MS. MS spectra were recorded on a Thermo Quest Finningan LCQTM 
DECA ion trap mass spectrometer, equipped with a Finnigan ESI interface; data were 
processed by Finnigan Xcalibur software system. All reactions were monitored by TLC on 
silica gel 60 plates (Merck).  
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Effect of GM1/GD1a and their oligosaccharides on neuronal morphology  
It has been known for long time that exogenously administered GM1 induces the 
differentiation of murine N2a neuroblastoma cells and it has recently been observed that the 
administration of the oligosaccharide component alone induces the same neuritogenic effect, 
demonstrating that GM1 sugar is responsible for this effect (Chiricozzi et al. 2017). We 
therefore investigated the effect of exogenous administration of GM1 and its more complex 
catabolic precursor GD1a, on the morphology of CGN, adding them to the culture medium 
from time zero at the final concentration of 50 µM. Figure R1 shows the representative 
images of optical microscopy acquired after 24, 48 and 72 h of the CGN grown in the absence 
(CTRL, first line) or in the presence of GM1 (GM1, second line) or GD1a (GD1a, third line), 
which show that both gangliosides seem to accelerate the process of differentiation of 
granular progenitors by speeding up clustering and the emission of neuronal prolongations. 
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At this point we investigated whether analogue morphological effect occurred following the 
administration of the respective oligosaccharide chains of GM1 (oligoGM1) and GD1a 
(oligoGD1a). Figure R2 shows the representative images of optical microscopy of cerebellar 
granular progenitors grown in the absence (CTRL, first line) or in the presence of oligoGM1 
(oligoGM1, second line) or oligoGD1a (OligoGD1a, third line) added to the culture medium 
at time zero at a concentration of 50 µM. 
 
  
Figure 1R. Morphological effect of exogenous administration of gangliosides GM1 and GD1a 
to cerebellar granule neurons during development. CGN were dissociated from mice cerebellum 
and plated in the absence (CTRL, first line) or in the presence of 50 µM of GM1 (second line) or of 
GD1a (third line). Representative phase contrast microscopy images with 100 x magnification 
obtained after 24, 48 and 72 h from cell plating (n=8) are reported. 
Figure 2R. Morphological effect of exogenous administration of gangliosides oligosaccharides 
oligoGM1 and oligoGD1a to cerebellar granule neurons during development. CGN were 
dissociated from mice cerebellum and plated in the absence (CTRL, first line) or in the presence of 
50 µM oligoGM1 (second line) or  oligoGD1a (third line). Representative phase contrast microscopy 
images with 100 x magnification obtained after 24, 48 and 72 h from cell plating (n=8) are reported. 
 Results  
44 
 
In this case only the oligoGM1 has shown to induce an acceleration of the clustering and the 
neuritogenesis of the CGN with respect to the untreated control cells, while the cells grown 
in the presence of oligoGD1a seem to follow maturation times analogous to the control cells. 
We also performed an immunofluorescence analysis on cells grown in the absence or in the 
presence of oligoGM1 using antibodies directed against neurofilament proteins, which 
characterize neuronal extensions and increase during neuron maturation, allowing to follow 
the organization and the neuronal disposition in culture. As shown in Figure R3, the CGN 
show longer extensions and a more complex arrangement after 48 h incubation with 
oligoGM1 with respect to controls. The DAPI staining of the nuclei shows a more organized 
disposition of the cell bodies in oligoGM1-cells, with an accentuated degree of aggregation. 
 
Hence, in the presence of oligoGM1 as well as of GM1 and GD1a, CGN show typical 
clusters already following 24 h in culture and more complex neurite network compared to 
cells grown with oligoGD1a or untreated ones. 
Even in primary neurons, the oligosaccharide component of GM1 appears to be responsible 
for the morphological effects of the entire GM1 and of its precursor GD1a. For this reason, 
Figure 3R. Immunofluorescence analysis of Neurofilament proteins in CGN under oligoGM1 
administration. Representative immunofluorescence images with 100x magnification for nuclei 
(DAPI - blue), Neurofilament proteins (green), and merged signal (MERGE) following 48 h from 
neurons plating (n=3).  
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we focused on oligoGM1 characterizing its effect on neuronal motility and the underlying 
mechanism of action. 
Effect of oligoGM1 on neuronal motility 
To better investigate the influence of oligoGM1 on neuronal motility, time lapse recordings 
of neuronal cultures in the presence and absence of oligoGM1 using the Incucyte® Live Cell 
Analysis System (Sartorius) were performed. The frames were acquired every 2 h for 24 h. 
Video cuttings representing the acquired fields are shown in Figure 4R (panel A). The graph 
reported in Figure 4R (panel B) shows that the cells incubated with oligoGM1 have a 
significantly higher degree of clustering than controls starting from 8 h in culture and lasting 
for all 24 h. 
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Figure 4R OligoGM1 effect on neuron clustering. The CGN were plated with or without 50 µM 
oligoGM1 and in-live recorded acquiring 1 frame every 2 hours for 24 hours via IncuCyte. a) Time 
lapse frame cuttings acquired with a magnification of 100 X at the times indicated. The clusters 
automatically defined by the IncuCyte S3 2018A software are highlighted in yellow. b) Cell 
clustering rate quantification carried out by IncuCyte S3 2018A software. White circles represent 
neurons cultured in the absence of oligoGM1 and black circles represent neurons grown in oligoGM1 
supplemented medium. Results are expressed as the mean ± SEM of cluster confluence percentage 
from three different experiments (*p<0.05 vs. CTRL, two-way ANOVA, n=3). 
 
OligoGM1 impact on focal adhesion protein activation 
To biochemically characterize the effect of oligoGM1 on neuronal migration, we 
investigated the involvement of focal adhesion proteins. FAK is activated by several 
extracellular stimuli such as those arising from adhesion receptors (integrins) and receptors 
for neurotrophins. The active form of FAK is phosphorylated on tyrosine 397 and in primary 
neurons it was found to form a complex with the Src kinase, activated in turn by 
phosphorylation. (Tucker et al. 2008; Carragher et al. 2004). In this way FAK and Src recruit 
a series of proteins involved in the actinic cytoskeletal remodeling, necessary to allow 
motility and growth of the axonal cone. Among these proteins there are, for instance, 
paxillin, vinculin and the small GTPases proteins.  
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As shown by immunoblotting represented in Figure 5R, after 24 h from oligoGM1 
administration, an increased phosphorylation levels of both FAK and Src kinases was found. 
It was reported that during neuronal development the expression of Rac3 protein, a small 
GTPase belonging to Rho-GTPase family, is specifically induced to regulate neuritogenesis 
and neuron migration (Albertinazzi et al. 1998; Corbetta et al. 2009). Interestingly, an 
increased level of Rac3-GTPase protein in CGN cells supplemented with oligoGM1 with 
respect to controls following 24 h of plating was pointed out (Figure 5R).  
 
OligoGM1 influence on the expression of neuronal marker proteins 
During neuronal differentiation, development and maturation, there is a significant change 
in the expression of specific genes coding for structural proteins and enzymes required for 
proper neuronal function. The effect of oligoGM1 on the protein pattern of cultured neurons 
was evaluated, investigating neuronal markers whose expression progressively increase 
during neuritogenesis and maturation such as Neuroglycan C and β3 tubulin, which are 
Figure 5R OligoGM1 effect on the expression and activation of focal adhesion proteins. CGN 
were incubated in the absence (CTRL) or in the presence of 50 µM oligoGM1 for 24 h. Expression 
of FAK, P-FAK (tyr 397), Src, P-Src (tyr 416), and RAC3 were carried out by specific antibodies 
and signals were revealed by enhanced chemiluminescence. Bottom: representative immunoblotting 
images are shown. Top: semi-quantitative analysis of P-FAK and P-Src signals related to total level 
of FAK and Src, respectively; RAC3 was normalized on GADPH level, used as internal normalizer. 
Data are expressed as fold increase over control of the mean ± SEM from five different experiments 
(*p<0.05, Student’s t-test, n=5). 
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constituents of neuronal protrusions, and Synapsin I which is part of the synaptic density 
(Aureli et al. 2011; Ngamukote et al. 2007). 
As shown in the Figure 6R (panel A) following 24 h from oligoGM1 administration, CGN 
have been found to express increased protein level of all tested markers with respect to 
untreated neurons.  
In parallel the mRNA level of the aforementioned markers was verified, using quantitative 
PCR. RNA was extracted and retrotranscribed from neuronal lysates. The graphs reported 
in Figure 6R (panel B) show that the transcript level of neuronal markers undergoes a 
significantly increase in the CGN after 5 h of incubation with oligoGM1 compared to the 
untreated controls. After 12 and 24 h in culture, the mRNA levels of the markers remain 
higher in the oligoGM1 treated CGN compared to the controls, but at a lower extent. 
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Figure 6R OligoGM1 effect on the expression of neuronal markers. CGN were plated in the 
absence (CTRL) or in the presence of 50 µM oligoGM1. The expression of Neuroglycan C, β3-
tubuline and Synapsine I was evaluated both at protein and at transcript level. a) Western blotting 
analysis of cell lysate after 24 h from cell plating by means of specific antibodies and revealed by 
enhanced chemiluminescence. GADPH was used as internal normalizer. On the left, representative 
immunoblotting images are shown. On the right, relative quantitation of protein signals is reported. 
Data are expressed as the mean ± SEM of fold increase over control from five different experiments 
(*p<0.05, Student’s t-test, n=5). b) RT-PCR after 5, 12 and 24 h from cell plating. Hprt gene was 
used as internal normalizer. The relative expression level is indicated as mean ± SEM of three 
different experiments (Student’s t, n=3).  
 
Dynamics of the ganglioside pattern under the influence of oligoGM1 
Glycosphingolipids and their sialic acid‐containing derivatives, gangliosides, are important 
cellular components and are abundant in the nervous system. They are known to undergo 
dramatic changes during brain development. Gangliosides are particularly represented in the 
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membrane of neurons. During differentiation and maturation in vitro, as well as in vivo, the 
composition of neurons’ gangliosides changes drastically, both to define the peculiar 
membrane geometry of the synapses, and to constitute the important signaling platforms 
characterized by the enrichment of gangliosides, i.e. lipid rafts. The simplest gangliosides 
such as GM3 and GD3 are more represented in neuronal precursors, where instead more 
complex gangliosides are less expressed. During maturation and neurites extension, complex 
gangliosides such as GM1, GD1a, GD1b and GT1b increase progressively and their levels 
remain high until senescence (Van Echten-Deckert et al. 2006; Aureli et al. 2011). In mature 
neurons, on the other hand, the quantity of simpler gangliosides, especially GM3, is reduced.  
Therefore, the possible effect of exogenous administration of oligoGM1 on the dynamics of 
the ganglioside pattern of CGNs was evaluated, focusing on the time of 24 h of culture, 
where an effect of GM1 oligosaccharide on the expression of neuronal protein markers was 
detected. 
The cells were plated directly in the presence or absence of oligoGM1 and were collected 
and lysed after 24 h. The lipids were then extracted as in the Materials and Methods section 
and the gangliosides were separated from the neutral lipids by the Folch partitioning (Folch 
et al. 1957) within the aqueous phase. The different species of gangliosides were separated 
by hpTLC and revealed with the Anisaldehyde reagent. A representative image of the hpTLC 
plate is shown in Figure 7R. The intensity of each band, corresponding to the specific lipid 
species, has been normalized with respect to the protein content in the samples and compared 
to the levels of the control. The graph on the right shows the quantification of gangliosides 
where it is highlighted that in the presence of oligoGM1 CGN express higher levels of GM1 
ganglioside while GM3 is slightly less expressed. 
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Figure 7R. OligoGM1 effect on CGN endogenous gangliosides. The endogenous gangliosides 
were separated from total lipid extract obtained from neurons cultured in the absence (CTRL) or in 
the presence of 50 µM oligoGM1 for 24 h. Ganglioside pattern resolved by hpTLC in the presence 
of specific standards and revealed by anisaldehyde spry reactive. On the left: hpTLC plate 
representative image of neuron ganglioside pattern. On the right: relative quantitation of the intensity 
of each ganglioside band normalized on the protein content. Data are expressed as the mean ± SEM 
of fold increase over control from three different experiments (*p<0.05, Student’s t-test, n=3).  
 
In addition, we followed the expression of complex gangliosides over time, by using Ctx-B-
HPR as detection technique. The Figure 8R reports the results of the Ctx-B-HRP staining 
analysis following treatment with sialidase on TLC plate, performed after separation of the 
gangliosides extracted from CGN grown in the presence or in the absence of oligoGM1 for 
12, 24, 48 and 72 h. The graphs on the bottom show the quantification of each lipid species 
normalized to protein content. Already starting from 12 h in culture the CGN treated with 
oligoGM1 show greater levels of complex gangliosides which remain higher than the 
controls even after 72 h. 
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Figure 8R Time course effect of oligoGM1 on the CGN ganglioside composition detected by 
Ctx-B-HRP staining. The CGN were plated in the absence (CTRL) or in the presence of oligoGM1. 
After 12, 24, 48 and 72 h the lipids were extracted, and the gangliosides separated as described in 
the Methods section. The ganglioside species were resolved by hpTLC in the presence of defined 
standards determined of 10 pmol and detected by staining with Ctx-B-HRP following reaction with 
sialidase on the hpTLC plate. On the top, the representative image of the hpTLC plate. Below are the 
graphs of the quantifications of the levels of each lipid expressed as mean ± SEM of pmol per mg of 
total proteins from three different experiments (n = 3, Student T test, CTRL vs oligoGM1, p <0.05). 
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Fate of [3H]-oligoGM1 added to primary neurons 
Recently, in neuroblastoma cell line N2a, oligoGM1 was found to activate differentiating 
program by interacting with cell surface without entering into the cells (Chiricozzi et al. 
2017). 
In order to characterize the molecular mechanism underlying oligoGM1 effect also in 
primary neurons, we investigated how oligoGM1 could interact with cultured CGN 
following the procedure previously used (Chigorno et al. 1985; Chiricozzi et al. 2017). CGN 
were cultured in the presence of isotopic tritium labeled [3H]-oligoGM1 for 0.5, 1, 4, 6, 12 
and 24 h. At the end of the incubation, neurons were firstly washed with culture medium 
containing 10% serum in order to collect the fraction of oligosaccharide weakly associated 
to the cells’ surface; this one represented the serum labile fraction. Subsequently cells were 
washed with a solution containing low concentrated trypsin to remove the possible fraction 
strongly bond to the cell surface, corresponding to the trypsin labile fraction. At the end, 
cells were lysed obtaining the fraction of internalized [3H]-oligoGM1 corresponding to the 
trypsin stabile fraction. The graph in Figure 9R shows the radioactivity values measured in 
each fraction for all the times considered. At each time point analyzed, about 99% of [3H]-
oligoGM1 was found in the serum labile form suggesting that the oligoGM1 is not taken up 
by the cells but rather it weakly associate to neuron plasma membrane. 
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Figure 9R Association of [3H]-oligoGM1 to CGN. CGN were incubated with 50 μM [3H]-
oligoGM1 for 0.5, 1, 4, 6, 12 and 24 h. After pulse, cells were washed with medium containing 10% 
FBS to obtain the serum labile fraction (SL). Then cells were washed with low concentrated trypsin 
solution to obtain the trypsin labile fraction (TL). Finally, cells were lysed to obtain trypsin stable 
fraction (TS) corresponding to the fraction of compound internalized by cells. The radioactivity 
associated with each fraction was determined by liquid scintillation counting. Data are expressed as 
mean ± SEM of total radioactivity percentage from three different experiment (n=3). 
 
TrkA-MAPK pathway as the mediator of oligoGM1 prompted neuronal 
maturation 
In primary neurons, as well as in N2a neuroblastoma lines, the oligoGM1 is not internalized 
by the cells, so its effects could probably be derived by an action at the level of the plasma 
membrane. Furthermore, taking into account the reported effect prompted by GM1 on TrkA 
mediated neuronal differentiation (Farooqui et al. 1997; Singleton et al. 2000, Duchemin et 
al. 2002; Da Silva et al. 2005; Mocchetti 2005; Zakharova et al. 2014) and considering the 
recent result in neuron-like N2a cells, where oligoGM1 was found to increase TrkA 
phosphorylation (Chiricozzi et al. 2017, 2019a, 2019b), we investigated the activation of the 
TrkA-MAPK pathway with the aim of identifying the molecular effectors of oligoGM1 in 
CGN. 
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Thus, we performed a time course analysis collecting the neurons after a few minutes up to 
3 h following oligoGM1 administration and evaluating, by western blotting, the 
phosphorylation status of the TrkA receptor and MAPK ERK1/2.  
 
 
Figure 10R OligoGM1 effect on TrkA-ERK1/2 pathway. CGN were culture in the absence 
(CTRL) or in the presence of 50 µM oligoGM1. Expression of TrkA, P-TrkA (tyr490), ERK1/2 and 
P-ERK1/2 by specific antibodies and signals were revealed by enhanced chemiluminescence. Top: 
representative immunoblotting images. Bottom: semi-quantitative analysis of spots’ signals of 
phosphorylated TrkA and ERK1/2 related to signals of total TrkA and ERK1/2, respectively. Data 
are expressed as mean ± SEM of the fold increase over control from five experiments (*p<0.05, 
Student’s t-test, n=5). 
 
TrkA activation 
As reported in the blotting of Figure 10R (panel A) we observed a hyperphosphorylation of 
TrkA on tyrosine 490 after only 10 min from the administration of oligoGM1 which remains 
higher than the control cells for 30 min. This difference disappears 1 h after sugar 
administration.  
 
ERK1/2 pathway 
After 10 and 30 min from administration of oligoGM1, no difference in ERK1/2 
phosphorylation was seen in treated neurons compared to controls. Only after 1 h the 
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oligoGM1 treated neurons had a higher level of ERK1/2 phosphorylation than the controls, 
which returned to equalize the untreated neurons after 3 h.  
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Discussion 
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The role of gangliosides and specifically GM1, in nervous system homeostasis has been 
known for several decades and many GM1-modulated molecular partners have been 
identified over the years. Moreover, in 2017 a research hypothesis, advanced in 1988 by 
Shengrund and Prouty (Shengrund and Prouty 1988), was resumed according to which an 
essential role for GM1 to carry out its plasma membrane mediated functions should be 
attributed to its oligosaccharide portion (Chiricozzi et al, 2017). The exploration of GM1 
oligosaccharide functionalities was performed in neuron-like cells, i.e. murine N2a 
neuroblastoma cells, where it was shown that the pentasaccharide (β-Gal-(1-3)-β-GalNAc-
(1-4)-[α-Neu5Ac-(2-3)-]β-Gal-(1-4)-Glc, coded II3Neu5Ac-Gg4) was the only bioactive 
component of GM1 ganglioside, responsible for its neuritogenic and protective properties 
(Chiricozzi et al, 2017; 2019a; 2019b). 
Here, therefore these findings were translated in a more physiological context by using 
primary cultures of precursors of murine cerebellar neurons, with the aim to dissect the GM1 
molecular mechanism regarding the differentiation processes.  
To do that, the potential effects of GM1, its direct anabolic successor/catabolic precursor 
GD1a, and their oligosaccharides where exanimated on the process of neuronal 
differentiation and maturation in vitro. 
Both GM1 and GD1a gangliosides applied induced an acceleration of the development of 
neurons, which can be deduced from a more rapid formation of neuronal clusters, which 
corresponds to the first phase of the maturation process of these neurons in vitro (Bilimoria 
et al. 2008) (Figure 1R). It should be noted that this effect occurred starting from the first 
hours of culture, where the cell body clusters were visibly more numerous and populated in 
the presence of gangliosides and continued until the third day where the differences between 
cells incubated with and without gangliosides were smoothed. The same morphological 
effect was observed when GM1-oligosaccharide was administered, whereas the GD1a-
oligosaccharide administration provided no difference recorded with respect to the control 
cells (Figure 2R). This suggests that even in primary neurons the oligoGM1 accounts for the 
effect of the whole GM1, while the oligoGD1a does not account for the effect of the whole 
GD1a. As with GM1, when GD1a is administered exogenously, it is taken up by cells and 
becomes an additional component of plasma membranes (Saqr et al. 1993). It is possible to 
speculate that the exogenously administered and stably inserted GD1a in the neuron 
membrane is converted to GM1 by cellular plasma membrane sialidases (Miyagi et al. 2012). 
In fact, GD1a is known to cluster with GM1 and sialidases with a role of reserve pool of 
GM1 (Sonnino et al. 2011). In this way the morphological effect observed following the 
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administration of GD1a could be ascribed to the GM1 deriving from its desialylation and 
more likely to GM1-oligosaccharide component since GD1a-oligosaccharide alone is not 
able to exert the same effect. 
Since as in N2a cells, oligoGM1 exerted a morphological effect similar to that of GM1 (and 
GD1a), we focused our subsequent analyzes only to oligoGM1, to fully characterize the 
GM1 mechanism of action. 
OligoGM1 influence on neuron migration has been analyzed in more detail through live 
imaging. The time lapse analysis recorded a significant increase of neuron-clustering rate in 
the presence of oligoGM1 starting from 8 h in culture which remained higher than the 
controls for all the 24 h of analysis (Figure 4R). The increased aggregation state is observed 
even after 48 h where the immunofluorescence for neurofilament proteins has also 
highlighted a more complex neuronal network formed by the CGN grown in the presence of 
the oligoGM1 with respect to the controls (Figure 3R). 
The biochemical explanation of this morphological effect is revealed by the increase in the 
pFAK(Y397)/FAK ratio evaluated by immunodetection, in oligoGM1 grown cells, 
accompanied by the elevation of the pSrc(Y416)/Src ratio (Figure 5R). Accordingly, in 2014, 
Navarro and co-workers defined the focal adhesion kinase FAK functioning as a sort of 
"orchestra director" that coordinates a wide range of signaling pathways during neuronal 
motility and growth of axons and dendrites (Navarro and Rico 2014). In fact, FAK associates 
with and activates the kinases of the Src family and in combination they recruit an array of 
other proteins involved in the actin cytoskeletal remodeling, an event required both for the 
advancement of the leading edge of a lamellipodium, and for the growth of neuritic 
prolongations (Tucker et al. 2008; Carragher et al. 2004). 
In addition, the observation of increased levels of Rac3-GTPase in CGN grown in the 
presence of oligoGM1 further supports the role of the saccharide in stimulating neuron 
migration during the early stages of development as Rac3-GTPase is reported to be 
specifically expressed during the early stages of neuronal migration (Bolis et al. 2003; De 
Curtis et al. 2014). 
Beyond the migratory aspect, we found that oligoGM1 accelerated all changes in the protein 
and lipid pattern that normally occur during the process of neuronal differentiation and 
maturation. After 24 h the CGN expressed higher levels of specific neuronal protein markers 
when cultivated in the presence of oligoGM1 with an increase in the respective transcript 
levels observable already 5 h after the saccharide administration (Figure 6R). Furthermore, 
even the shift from simplest gangliosides towards the expression of more complex 
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gangliosides was accelerated by oligoGM1 (Figure 7R). During neuronal differentiation and 
complete maturation, neurons reduce the expression of the simplest gangliosides (GM3, 
GD3) while the most complex ones increase with GM1, GD1a, GD1b and GT1b representing 
the main gangliosides belonging to completely differentiated neurons (Yu et al. 2008, 
Prinetti et al. 2001; Aureli et al. 2011). Already after 12 h in culture in the presence of 
oligoGM1, the CGN expressed higher levels of the four main complex gangliosides and after 
24 h there was a decrease in GM3 levels compared to the control cells (Figure 7R, 8R). 
Overall, oligoGM1 appeared to act as a stimulant and enhancer of the mature neuronal 
phenotype: the exogenous administration of oligoGM1 could anticipate the physiological 
increase of plasma membrane GM1 and thus driving in advance all the related events due to 
the presence of GM1. 
 
The discovery of the oligosaccharide associated almost exclusively with the serum-labile 
fraction, weakly associated with the plasma membrane, indicated that the saccharide 
remained in the extracellular environment without being internalized by neurons. In fact, no 
radioactivity associated with oligosaccharide, when used as a radio-labeled derivative, was 
measured in neuronal lysates (Figure 9R). This datum suggests that, similarly to what was 
observed in neuroblastoma cells (Chiricozzi et al. 2017; 2019a), the oligosaccharide induces 
the morphological effect acting at the level of the plasma membrane. With the aim of 
identifying a pathway that could act as a mediator of the effects of oligoGM1 and then initiate 
the cascade of events at the plasma membrane level, we investigated the involvement of the 
TrkA-MAPK pathway, already known to be a GM1 target (Farooqui et al. 1997; Singleton 
et al. 2000; Duchemin et al. 2002; Da Silva et al. 2005; Mocchetti et al. 2005; Zakharova et 
al. 2014) and found to be up-regulated by oligoGM1 in N2a cells (Chiricozzi et al. 2017; 
2019b).  
Our results indicate a rapid up-phosphorylation of the TrkA receptor, at the level of tyrosine 
490, which occurs already 10 min after oligoGM1 administration and persists for another 20 
min (Figure 10R, A). Only after 1 h the increase in ERK1/2 phosphorylation is appreciated, 
whereas at earlier times no significant difference in activation of the ERKs with or without 
oligoGM1 has been detected (Figure 10R, B). Since ERK is a terminal transducer 
downstream of a signal transduction cascade that involves other intermediaries in the middle, 
the delay of the enhanced activation between TrkA and ERK could be due to the presence 
of the many other factors of the cascade. The interaction between the extracellular portion 
of TrkA and the GM1 oligosaccharide has already been observed in N2a neuroblastoma cells 
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and characterized by bioinformatic molecular docking experiments (Chiricozzi et al. 2017). 
It is reasonable to think that the increase in TrkA phosphorylation induced by oligoGM1 in 
the CGNs is due to a direct association between the two molecules, also in this context. 
Interplay between TrkA and activation of FAK, Src and MAPK has already been found in 
peripheral DRG neurons, where the application of NGF led to the activation of TrkA, FAK, 
Src and MAPK, events necessary for neuritic outgrowth (Tucker et al. 2008). The 
observation of TrkA-MAPK pathway activation following the administration of oligoGM1 
together with the discovery of increased pFAK and pSrc levels suggests that there is an 
association between the oligoGM1-induced MAPK pathway and the activation of the 
regulators of focal adhesions, which are directly responsible for neuronal motility and the 
lengthening of neuronal processes. The morphological differences are accompanied by the 
activation of cellular signaling processes that finally lead to an acceleration of differentiation 
processes both from protein and lipid point of view.  
The present work demonstrates that the GM1 oligosaccharide is able on its own to exert the 
same enhancer effect on the neuronal development as GM1 does, confirming what was 
observed on N2a cells (Chiricozzi et al. 2017). The morphological effect basically concerns 
an acceleration of motility and therefore of the clustering process, together with the 
strengthening of the neuronal network. As summarized in the diagram of Figure D1, this 
effect is due to an action at the level of the plasma membrane related to a rapid enhancement 
of the Trka-MAPK pathway activation. This event is associated with increased activation of 
FAK and Src, the main regulators of the array of proteins involved in the turnover of focal 
adhesions, responsible in turn for neuronal mobility and neuritic growth, all accompanied by 
a parallel increase in proteins and lipids typically associated to neuronal maturation phase.  
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Figure D1. Schematic representation of molecular mechanism underling GM1-
oligosaccharide enhanced neuronal maturation. OligoGM1 enhances the activation of 
TrkA-MAPK pathway which could be associated to an increase of FAK and Src activation, 
regulators of the array of proteins of focal adhesion complex responsible for neuronal 
motility and axon growth. 
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